CD44 and acute myeloid leukemia: Blocking CD44, the most commonly variant of which expressed in AML is v6 that is moreover linked to poor outcome, has been shown to prevent persistence of AML blasts in the bone marrow niche upon chemotherapy, which is otherwise linked to the quiescent-promoting- and, thus, cell-protective TME functions of CD44 (57).